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Smart polymeric systems are required that are able to release a therapeutic drug with controlled 
delivery. Herein we investigated the pH triggered release of ibuprofen from a polymeric nanoparticle 
system prepared using ring-opening metathesis polymerisation. The co-polymerisation of ibuprofen 
and poly(ethylene)glycol monomers followed by self-assembly produced a nanoparticle system that 
was shown to be stable at neutral pH but releases ibuprofen in alkaline conditions. 
 
Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) possess analgesic, antipyretic and anti-inflammatory 
properties and are amongst the most widely prescribed drugs worldwide.1 Pain relief is the primary 
clinical use for NSAIDs but the well-known association between inflammation and cancer has resulted 
in numerous investigations of NSAIDs for cancer prevention and treatment. Studies in various types of 
breast cancers, including prostrate2, breast3, colorectal4,5 and ovarian6 cancers indicate a positive 
effected linked to NSAID use. NSAIDs typically act by blocking the cyclooxygenase (COX) enzyme which 
is key in the synthesis of prostaglandins (PGs) which are required for the vasodilation associated with 
inflammation. There are however also epidemiological studies that contraindicate NSAID use which are 
associated with increased cancer risks, especially renal7, although the mechanism of action is unclear1. 
Furthermore NSAIDs have been associated with unwanted nausea and dyspeptic symptoms including 
ulcers1,8 and internal bleeding9. These latter complications are related to the oral ingestion of NSAIDs 










The field of polymer therapeutics spans several decades and works on the development of polymer-
drug systems that rely on a degradable or bio-degradable process to release a drug from a polymer11. 
There are several advantages in using these poly-prodrug systems, such as an increase in the drug water 
solubility, an enhancement of drug bioavailability, protection of the drug during its circulation to the 
site of action and an improvement in pharmacokinetics12,13. In cancer therapy the enhanced permeation 
and retention (EPR) effect is also a common property associated with therapeutic macromolecules14,15 
although this effect is questioned in human cell studies16. Having previously made a pure drug platform 
from salicylic acid17, we were interested in utilising the ring opening metathesis polymerisation (ROMP) 
process as a means of approaching a controlled drug release polymer system. The exquisite control that 
ROMP affords  in preparing well-controlled functionally dense polymers and copolymers18,19 and their 
resulting self-assembly has led to several examples of bio-related and therapeutic ROMP polymers20–26. 
Chemically degradable ROMP polymers, in other words when the mechanism of drug release is a 
chemical process such as ester hydrolysis and not a biological process, is an area that is gaining more 
attention27–29. Previous work in our laboratories has shown that the copolymerisation of a polyethelene 
glycol (PEG) moiety in peptide derived ROMP polymer leads to self-assembled molecular 
architectures30,31 and we were interested in investigating the stability and release of a non-steroidal 
anti-inflammatory drug (NSAID), namely ibuprofen, from a ROMP-PEG polymer systems. Nanoparticles 
derived from ROMP-PEG polymers have been shown to exhibit good stealth properties in tumour 
therapy studies27 and the excellent living control polymerisation of ROMP allows for the post-released 
scaffold to be under 45 kDa, a requirement for renal excretion32.  For this study we were considered 
four environments: aqueous, phosphate buffered saline (PBS), foetal bovine serum (FBS), pig liver 
esterase (PLE) and basic (2M NaOH in water). 
Results and Discussion 
Monomer synthesis 
The monomers required for this investigation are not commercially available. Condensation reactions 
with the exo-carbic anhydride derivative 1 were chosen as these lead to symmetrical norbornene 
derivatives which minimise head to tail effects. The norbornene PEG-derivative 2 was prepared in a 
similar route to a previously reported methodology within the group31, whereas the ibuprofen 
derivative 4 was prepared from N-(hydroxypentanyl)-cis-5-norbornene-exo-2,3-dicarboximide 333, 
(Scheme 1). 
 Figure 1 Synthesis of PEG-Ibuprofen copolymers 
Synthesis of polymers 
The monomers 2 and 4 were polymerised respectively, using the commercially available Grubbs G3 
initiator34 in THF at room temperature and were terminated with ethyl vinyl ether. 
The individual homopolymers were readily formed and after isolation they were characterised by 
proton NMR and GPC (data presented in Table 1). The polydispersity of the PEG polymer poly-2 was 
slightly higher than for poly-4 and may be a reflection of the PEG chain length of the monomer which 
is itself an average distribution. 
Table 1: polymerisation characteristics for poly-2 and poly-4. 



















Poly-2  5 min >99 92 14 852 16 947 10 984 14 229 1.36 
 Poly-4  5 min >99 98 8 752 8 755 11 116 13 640 1.27 
 
To obtain the block co-polymer poly(4-b-2), the exo-norbornenyl ibuprofen monomer 4 was firstly 
polymerised using a ratio of monomer to G3 initiator of 20:1 and dry DCM as solvent. After 10 minutes 
an equimolar quantity of exo-norbornenyl PEGOMe monomer 2 was added to the reaction mixture 
giving an overall ratio of monomer to initiator of 40:1. Statistical copolymer poly(4-co-2) was 
synthesised by adding both of monomers (1:1 molar ratio) at the same time, into the G3 initiator 
solution. In each case the polymerisation was terminated by adding ethyl vinyl ether and the pure 
polymer was obtained by precipitation with diethyl ether (Figure 1).  
It was found that both copolymers poly(4-b-2) and poly(4-co-2) possessed a polydispersity index lower 
than 1.4 and a number average molecular weight, Mn that is comparable with the theoretical one. For 
the block copolymer poly(4-b-2) it was also possible to estimate the average molecular weight from end 
group analysis from the proton NMR. 
  
Table 2: polymerisation characteristics of block and statistical copolymer derived from 2 and 4. 
















Poly(4-b-2) 78 36 64 21 895 24 632 19 318 24 905 1.29 
 
Poly(4-co-2) 76 37 63 22 017 n.a. 19 263 26 191 1.36 
 
Self-assembly of block and statistical copolymer 
Self-assembly of the copolymers mentioned above were obtained by dissolving the polymer (< 10 mg) 
in 1 mL of acetone, and deionised water was added dropwise, over a prolonged time to the stirred 
solution to give a polymer with a final concentration of 1 mg/mL. The aggregate solution was 
subsequently transferred into a dialysis membrane, sealed and dialysed against distilled water for 24 
hours to remove any traces of the organic solvent. The self-assembly was then analysed by DLS 
(Dynamic Light Scattering) and TEM (Transmission Electron Microscopy). DLS data was recorded using 
a polyphospholipid refractive index of 1.45.  
Figure 2 shows the DLS particle distribution for the block copolymer poly(4-b-2) in acetone, and of the 
statistical copolymer poly(4-co-2) also in 
acetone. This latter copolymer presents, as 
expected, a different distribution of the 
particle size; the largest peak (67% by 
intensity) is for particles at 13nm. Because of 
the random distribution of the PEG and 
ibuprofen side chains tethered to the 
norbornene backbone, we interpret this as 
the polymer folding in on itself, forming 
single chain nanoparticles. A small amount of 
these nanoparticles (32%) form random 
aggregates of a bigger size (230 nm) that 
precipitate in solution. TEM analysis of 
poly(4-co-2) confirmed an absence of 
ordered self-assembly. 
























The block copolymer, instead, behaves as a non-ionic amphiphilic polymer and in water forms particles 
in the size range of 50 - 600 nm as shown in Figure 6 with an average diameter of 196 nm in acetone.  
The self-assembled morphologies of the copolymers were studied using TEM. Samples were analysed 
on Formvar coated copper grids, to which a negative stain of uranyl acetate was added, that allows for 
better contrasting of low molecular weight atoms (C, H, N) under the electron beam.  
 
 
Figure 3: a) TEM image of block copolymer poly(4-b-2) ; b) distribution of the larger particles of image (a); d) distribution of 
the smaller particles of image (a). 
Figure 3a shows the TEM images obtained for the block copolymer poly(4-b-2). The image seems to 
reveal the presence of two different morphologies which can be considered vesicles and micelles. 
Figure 3b and 3c indicate that the copolymer poly(4-b-2) has a large distribution of particle size which 
ranges from 40 nm to 240 nm. Examining the histograms in more detail, it is possible to identify, for 
each plot, two different particle distributions. For example, in Figure 3b, there are two distributions 
centred at 70 nm and 120 nm respectively. These results do not entirely correspond to the DLS 
measurements, which provide a bigger average diameter, as is common due to the solvation sphere 
measured by DLS, and the compacting effect of the vacuum in TEM. Furthermore, Figures 3c indicates 
that the formation of spherical micelles is dominant, and they possess an average diameter of 30 nm. 
This result is in agreement with the calculations made using computational software, which afforded a 
repeating unit length of 0.617 nm that multiplied by the degree of polymerisation (DP = 40) gave a 
predicted particle radius of 25 nm. 
In vitro release studies  
Block copolymer poly(4-co-2) (200 µg) was placed into vials and 200 µL solutions of 2M NaOH in water, 
phosphate buffered saline (PBS), foetal bovine serum (FBS), pig liver esterase (PLE) and water were 
added to different sets of vials. The samples were incubated at 40 degrees in a thermocycler. Each 
sample was removed at predefined time points (2h, 4h, 8h, 24h, 48h, 96h), frozen and analysed 
afterwards by HPLC. A gradient processing method was used, starting from 20% methanol in water with 
0.1% of formic acid. Samples (10 µL) were run at 35 °C at a flow rate of 2 mL/min. Absorbance was 
monitored at λ = 225 nm. The instrument was calibrated using standard solutions of ibuprofen in 
methanol (50, 100, 150, 200, 250 ppm).  
Figures 4a and 4b illustrate the release of ibuprofen using basic conditions: Figure 4a shows the 
hydrolysis of ibuprofen using NaOH in water. It is possible to distinguish the characteristic peak of 
ibuprofen at a retention time around 3 minutes and 20 seconds. It is evident from the graphs, that 
ibuprofen can be slowly released over an extended duration of at least 4 days. By a prior calibration of 
the instrument, it is also possible to quantify the concentration of the released drug (Tables 4) which 
after 96h is in agreement with the theoretically expected value for quantitative hydrolysis. 
 
Figure 4: release study of ibuprofen with 2M NaOH in water. Chromatogram and the table including the concentration of 
ibuprofen released during time.  
As mentioned above, the hydrolysis of ibuprofen from block copolymers was investigated also using 
media that can mimic physiological conditions, such as PBS, FBS and PLE. By HPLC analysis, it appears 
that the polymer conjugate is stable as none of these media release ibuprofen at a temperature of 40 
°C. This suggests a polymer conformation which causes ibuprofen to be placed within the micelles 
where the proteins cannot hydrolyse the ester bond.  
Conclusion 
In summary we have shown that the block copolymerisation of norbornene monomers functionalised 
with polyethylene glycol and ibuprofen leads to the synthesis of a polymer which in an aqueous 
environment self-assembles to a nanoparticle system which in turn in an alkaline environment will 
release ibuprofen over a period of up to four days. Further work will explore different linkages between 
the polymer backbone and the drug with the aim of inducing controlled release in the presence of 
specific physiological environments.  
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